Skip to main content
NCBI home page
Oxidative Medicine and Cellular Longevity logoLink to Oxidative Medicine and Cellular Longevity
. 2017 Aug 13;2017:1913954. doi: 10.1155/2017/1913954

Corrigendum to “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway”

Yu Ah Hong 1, Keum Jin Yang 2, So Young Jung 2, Ki Cheol Park 2, Hyunsu Choi 2, Jeong Min Oh 2, Sang Ju Lee 1, Yoon Kyung Chang 1, Cheol WheePark 1, Chul Woo Yang 1, Suk Young Kim 1, Hyeon Seok Hwang 1,*
PMCID: PMC5572087  PMID: 28883900

In the article titled “Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway” [1], an acknowledgement should be added as follows:

The authors also wish to acknowledge the financial support of the Korean Society of Nephrology (JW Pharmaceutical, 2013).

References

  • 1.Hong Y. A., Yang K. J., Jung S. Y., et al. Paricalcitol Pretreatment Attenuates Renal Ischemia-Reperfusion Injury via Prostaglandin E2 Receptor EP4 Pathway. Oxidative Medicine and Cellular Longevity. 2017;2017:17. doi: 10.1155/2017/5031926.5031926 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Oxidative Medicine and Cellular Longevity are provided here courtesy of Wiley

RESOURCES